Single dose oral aceclofenac for postoperative pain in adults

Moore, Richard A.; Derry, Sheena; McQuay, Henry J

doi:10.1002/14651858.cd007588.pub2

Cited by 6 publications

(1 citation statement)

References 42 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3][4][5] Its antiinflammatory activity, and most of its other pharmacological effects, are due to inhibition of prostaglandin synthesis. 6 Diclofenac strongly inhibits cyclo-oxygenase isoforms in vitro and in vivo, thus decreasing the synthesis of prostaglandins, prostacyclin, and thromboxane products.…”

Section: Introductionmentioning

confidence: 99%

Efficacy, safety and tolerance of subcutaneous injection of high dosages of diclofenac in patients with neuropathic non-cancer pain and neuropathic cancer pain: Data from a clinical setting

2015

View full text Add to dashboard Cite

Diclofenac sodium is widely used for its anti-inflammatory and analgesic effects in the symptomatic treatment of acute and chronic inflammatory and painful conditions. The present observational study was carried out to investigate efficacy, safety, and tolerability of a new subcutaneous (SC) 75 mg/1 mL diclofenac hydroxypropyl-β-cyclodextrin (HPβCD) formulation for the treatment of neuropathic pain both in patients without cancer and in patients with cancer. A total of 105 outpatients and inpatients with moderate to severe neuropathic pain related to cancer (CP) and non-cancer (NCP), were selected if Numeric Rating Scale (NRS) ⩾7 and Pain Detect (PD) >16, and treated with 75 mg/1 mL SC HPβCD, according to a real clinical setting. The analgesic efficacy of the treatment, which was assessed during the study by questionnaire, was expressed in terms of reduction of 30-50% and >50% of baseline pain (NRS), after 1.5 h and 4 h from drug administration; tolerability and safety were assessed as well, and adverse events were recorded by an expert panel. In our study, a significant reduction in pain intensity (PI) after 1.5 h and after 4 h was observed for both groups of patients (CP and NCP). Different from what was detected in the CP group, a further and significant reduction of PI was obtained in the NCP group at 4 h (P <0.039). With regard to tolerability, while 90% of the patients did not complain of any adverse drug reactions, only 10% reported mild transient adverse reactions. SC administration of HPβCD has been proven effective and safe in the treatment of patients with moderate to severe neuropathic pain related to cancer or not, in a real clinical setting.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy, safety and tolerance of subcutaneous injection of high dosages of diclofenac in patients with neuropathic non-cancer pain and neuropathic cancer pain: Data from a clinical setting

2015

View full text Add to dashboard Cite

show abstract

Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews

Moore¹,

Derry²,

Aldington

et al. 2015

Cochrane Database of Systematic Reviews

Self Cite

183

166

View full text Add to dashboard Cite

show abstract

Non-prescription (OTC) oral analgesics for acute pain - an overview of Cochrane reviews

Moore¹,

Wiffen

Derry³

et al. 2015

Cochrane Database of Systematic Reviews

Self Cite

View full text Add to dashboard Cite

There is a body of reliable evidence about the efficacy of some of the most commonly available drugs and doses widely available without prescription. The postoperative pain model is predominantly pain after third molar extraction, which is used as the industry model for everyday pain. The proportion of people with acute pain who get good pain relief with any of them ranges from around 70% at best to less than 20% at worst; low doses of some drugs in fast acting formulations were among the best. Adverse events were generally no different from placebo. Consumers can make an informed choice based on this knowledge, together with availability and price. Headache and migraine were not included in this overview.

show abstract

Single dose oral aceclofenac for postoperative pain in adults

Cited by 6 publications

References 42 publications

Efficacy, safety and tolerance of subcutaneous injection of high dosages of diclofenac in patients with neuropathic non-cancer pain and neuropathic cancer pain: Data from a clinical setting

Efficacy, safety and tolerance of subcutaneous injection of high dosages of diclofenac in patients with neuropathic non-cancer pain and neuropathic cancer pain: Data from a clinical setting

Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews

Non-prescription (OTC) oral analgesics for acute pain - an overview of Cochrane reviews

Contact Info

Product

Resources

About